#United States #Atlanta #UCB #BIMZELX #bimekizumab

UCB's New Single-Injection Option for BIMZELX

In a significant development for patients dealing with chronic inflammatory diseases, UCB has announced that BIMZELX® (bimekizumab-bkzx) will now be available in the U.S. as a single 320 mg injection. This option aims to simplify administration for patients who require this specific dosage. The innovative delivery method comes in the form of a 2 mL prefilled syringe and an autoinjector, each capable of delivering the full dose with a single administration.

This new option offers added convenience compared to the previously available 1 mL devices that provide a 160 mg dosage. Camille Lee, the Head of U.S. Immunology at UCB, expressed enthusiasm regarding this advancement, highlighting that the company has received five new FDA-approved indications for BIMZELX within just over a year. This rapid progression underscores UCB's commitment to offering effective treatment options for individuals suffering from chronic inflammatory conditions such as moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderate-to-severe hidradenitis suppurativa.

The introduction of the 320 mg single-injection option was backed by clinical data assessing the bioequivalence between a single 2 mL subcutaneous injection and two 1 mL injections. Both methods showcased similar efficacy, affirming the reliability of the new administration route.

UCB aims not only to provide effective treatment but also to enhance the experience for patients through BIMZELX Navigate®, a dedicated patient support program. Enrolled patients will receive assistance from Nurse Navigators, who are available to discuss treatment plans, provide training for proper injection techniques, and connect patients with co-pay support resources. This proactive approach ensures patients stay informed about their treatment shipments and insurance statuses, making the entire experience smoother.

In addition to providing new options for administration, UCB is also engaging directly with payers to address access issues for patients needing BIMZELX. Their strategy emphasizes the need to keep patient welfare at the core of these discussions, ensuring affordability and accessibility in a sustainable manner.

Notably, the FDA has recommended the 320 mg dosage for multiple indications, including:

• - Plaque psoriasis: The regimen involves administering 320 mg at specific intervals, with adjustments for patients over a certain weight.
• - Psoriatic arthritis: A 160 mg dose is recommended, aligning with the patient's plaque psoriasis treatment.
• - Hidradenitis suppurativa: Treatment involves administering 320 mg initially over several weeks, followed by a maintenance schedule.

It’s crucial for patients to consult their healthcare providers for personalized treatment regimens and to discuss any potential risks or adverse effects associated with BIMZELX. The single-injection option is tailored to enhance patient experience and treatment adherence, ultimately aiming to improve outcomes in managing chronic inflammatory conditions.

For more information on BIMZELX and the available support services, patients can visit the official BIMZELX website or contact UCBCares® for assistance.

By broadening accessibility options and investing in patient support, UCB reaffirms its dedication to transforming the lives of those affected by severe immune system diseases. This launch is not just about a new product; it's about enhancing patient care and ensuring that effective treatments like BIMZELX are both accessible and manageable for everyone in need.